Arita Yuki, Taguchi Hiroaki, Kobayashi Mari, Tono Toshihiro, Ohsone Yasuo, Okano Yutaka
a Department of Internal Medicine , Kawasaki Municipal Kawasaki Hospital , Kawasaki , Japan and.
b Center for Arthritis and Rheumatic Diseases , Kawasaki Municipal Kawasaki Hospital , Kawasaki , Japan.
Mod Rheumatol. 2018 Nov;28(6):1041-1043. doi: 10.1080/14397595.2016.1181026. Epub 2016 May 16.
A 66-year-old woman who had rheumatoid arthritis and underwent a long-term treatment with methotrexate and etanercept developed Pneumocystis jirovecii pneumonia (PCP) 3 months after iguratimod add-on. Although most rheumatologists might have the impression that iguratimod has less toxicity and immunosuppressive effect compared with methotrexate and biologic disease-modifying antirheumatic drugs, this case suggests that iguratimod may increase the risk of PCP, especially in combination with other drugs.
一名66岁患有类风湿性关节炎且长期接受甲氨蝶呤和依那西普治疗的女性，在加用艾拉莫德3个月后发生了耶氏肺孢子菌肺炎（PCP）。尽管大多数风湿病学家可能认为，与甲氨蝶呤和生物性改善病情抗风湿药相比，艾拉莫德的毒性和免疫抑制作用较小，但该病例提示，艾拉莫德可能会增加PCP的发生风险，尤其是与其他药物联用时。
